Omega-3 LCPUFA supplementation improves neonatal and maternal bone turnover: A randomized controlled trial

• Published in: Journal of functional foods 2018-07, Vol.46, p.167-174
• Main Authors: Kajarabille, Naroa, Peña, Manuela, Díaz-Castro, Javier, Hurtado, Jose A., Peña-Quintana, Luis, Iznaola, Carmen, Rodríguez-Santana, Yessica, Martin-Alvarez, Estefanía, López-Frias, Magdalena, Lara-Villoslada, Federico, Ochoa, Julio J.
• Format: Article
• Language: English
• Subjects: Bone turnover; Docosahexaenoicacid (DHA); Pregnancy; Term neonates
• ISSN: 1756-4646; 2214-9414
• DOI: 10.1016/j.jff.2018.04.065

[Display omitted] •There no studies correlating DHA and bone turnover in pregnant women and neonates.•To evaluate the effect DHA during pregnancy and lactation on bone metabolism.•DHA supplementation modulates bone turnover during pregnancy and lactation.•DHA improves neonatal and maternal bone turnover. The aim of this study was to evaluate for the first time the effect of omega-3 LC PUFA supplementation during pregnancy and lactation on bone metabolism in mothers and neonates. 110 pregnant women were divided in two groups: control group (400 mL/day of the control dairy drink); supplemented group (400 mL/day of the fish oil-enriched dairy drink). Plasma bone biomarkers and mineral content in erythrocyte cytosol were assessed. In mothers, DHA supplementation increased OC and OPN levels and decreased IL-6 and TNF-α levels at delivery, increasing PTH levels during lactation. In neonates, DHA supplementation increased ACTH, insulin and leptin, decreasing RANKL and IL-6 in umbilical vein; increased OPG and leptin and diminished TNF-α in umbilical artery; increased OC levels, lowered PTH and TNF-α at birth. DHA supplementation during pregnancy and lactation has beneficial effects on bone turnover in both mother and neonates, representing a non-pharmacological pathway to decrease bone loss.